Sheffield cell therapy spinout Rinri secured corporate backing from Boehringer Ingelheim and UCB in a seed round that will drive work on stem cell-based treatments for hearing loss.

CIC has returned to supply AI forecasting platform Prowler.io with series B capital and help take the company's overall funding to $39m.

ETH Zurich spinout GetYourGuide secured $484m in a round led by SoftBank Vision Fund that took its total funding past $650m.

Pearson, Tencent and Mandatum Life helped supply the AI forecasting platform developer with series B capital that took its total funding to $39m.

M Ventures, Pfizer Ventures and Taiho Ventures all returned to help boost cancer drug developer Storm Therapeutics' series A round to $38.2m.

The Parkwalk-managed co-investment fund has supplied Cambridge cancer therapy spinout PolyProx Therapeutics with capital, augmenting a $4.4m seed round for the latter announced earlier this month.

Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.

Cambridge's cancer drug spinout Storm Therapeutics convinced its existing investors to join new participant Seroba Life Sciences for a second extension that brought its series A total to $38.2m.

Illumina Ventures and M Ventures made follow-on investments in synthetic DNA platform developer DNA Script as part of its $38.5m series B round.

Schulte Group has initiated corporate venturing activities through a new unit, Innoport, which will invest in startups developing technologies to transform the maritime transport industry.